Home > Insider Trading > Filing (0001104659-15-004406)

Filing Details

Accession Number:: 0001104659-15-004406
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-01-26 13:46:04
Reporting Period:: 2015-01-22

Filing Date:: 2015-01-26
Accepted Time:: 2015-01-26 13:46:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1135906	Epirus Biopharmaceuticals Inc.	EPRS	Pharmaceutical Preparations (2834)	043514457

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423641	Montreux Equity Partners Iv Lp	One Ferry Building, Suite 255 San Francisco CA 94111		No	No	Yes	No
1548152	Montreux Equity Partners V, L.p.	One Ferry Building, Suite 255 San Francisco CA 94111		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-01-22	14,130	$6.30	1,938,316	No	4	S	Direct
Common Stock	Disposition	2015-01-23	8,400	$6.27	1,929,916	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	271,476	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.36, inclusive. The Reporting Person undertakes to provide to EPIRUS Biopharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range reported.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range reported.
The securities reported herein reflect the 1-for-10 reverse stock split effected by the Issuer on July 16, 2014.
Represents shares of common stock ("Common Stock") of the Issuer directly held by Montreux Equity Partners IV, L.P. John J. Savarese, M.D., Howard D. Palefsky and Daniel K. Turner III are the managers of Montreux Equity Management IV, LLC, which is the sole general partner of Montreux Equity Partners IV, L.P. By reason of these relationships, Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.
Represents shares of Common Stock of the Issuer directly held by Montreux Equity Partners V, L.P. Daniel K. Turner III is the sole manager of Montreux Equity Management V, LLC, which is the sole general partner of Montreux Equity Partners V, L.P. By reason of these relationships, Montreux Equity Management V, LLC and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management V, LLC and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.